News & Media
ThriveRx Wins ASPEN Clinical Nutrition Team of Distinction Award
CINCINNATI, Ohio — Jan. 29, 2018 — ThriveRx, a division of Diplomat Specialty Infusion Group, has been recognized since 2013 for excellence in interdisciplinary clinical nutrition practice.
ThriveRx, the nutrition division of Diplomat Specialty Infusion Group, has been named a 2018 Clinical Nutrition Team of Distinction by the American Society for Parenteral and Enteral Nutrition (ASPEN).
“One of ASPEN’s highest achievements, this distinction is a true testament to the great clinical care and advocacy our team provides every day,” said Deb Pfister, director of nutrition. “Supporting our consumers with their therapies and everyday living is at the heart of what we do. We feel incredibly honored to receive this award.”
ThriveRx accepted its award during the ASPEN Nutrition Science and Practice Conference on Tuesday, Jan. 23, in Las Vegas, Nevada.
The Clinical Nutrition Team of Distinction program, launched in 2013, recognizes excellence in interdisciplinary clinical nutrition practice. Institutions, agencies, and communities that comply with ASPEN standards, guidelines, and values are eligible.
The award is aimed at recognizing those who are working to provide exceptional care to their patients each day. Clinical nutrition teams, as defined for this award, consist of a group of practitioners with a member from each of the four disciplines: dieticians, medicine, nursing and pharmacy.
ThriveRx originally received the distinction, which lasts five years, in 2013.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended Dec. 31, 2017, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) is the nation’s largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. The company offers medication management programs for people with complex chronic diseases and delivers unique solutions for manufacturers, hospitals, payers, providers, and more. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.